Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06610344 · ClinicalTrials.gov registry record · NA
BHB & CAR-T for Lymphomas
A NA study of Large B-cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06610344 is a NA study of Large B-cell Lymphoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 5 participants, below the 159-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06610344, a NA study of Large B-cell Lymphoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Additionally, this study will determine whether BHB supplementation leads to changes the gut microbiome and peripheral blood mononuclear cells (PBMCs). BHB supplementation will be performed through oral administration of HVMN Ketone-IQ, a commercially available BHB supplement, with an active ingredient of R- 1,3-Butanediol, which is converted to BHB.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT R-1,3-Butanediol
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2027-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06610344
The ClinicalTrials.gov registry entry for NCT06610344 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 159-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which R-1,3-Butanediol is the first listed.
NCT06610344 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06610344 about?
NCT06610344 is a clinical study titled "BHB & CAR-T for Lymphomas". The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Additiona...
What is the current status of trial NCT06610344?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2025-01-07. Estimated completion is 2027-09-15.
What conditions does trial NCT06610344 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06610344?
The interventions under investigation include: R-1,3-Butanediol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06610344?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06610344 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.